ArticleCureus2026
Dual-Frequency Non-invasive Monopolar Radiofrequency for Periorbital Tightening: Introduction of Novel Small Treatment Tips.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Objective and subjective retrospective evaluation of XERF, a novel single-shot dual-frequency non-invasive monopolar radiofrequency.Lasers in medical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periorbital aging involves progressive alterations in the dermis, superficial musculoaponeurotic system (SMAS), and ligamentous support, leading to eyebrow descent, upper-eyelid redundancy, and periorbital rhytids. Noninvasive monopolar radiofrequency (NMRF) is designed to address tissue laxity across multiple anatomical layers, yet conventional small applicators are limited by their shallow penetration, reducing their effectiveness. A novel dual-frequency NMRF platform (XERF, Cynosure-Lutronic, South Korea), incorporating two newly engineered small applicators, was developed to address this depth constraint. This report aims to describe our standardized approach to periorbital rejuvenation using XERF's novel small applicators, with the primary objectives of improving eyebrow position and achieving upper eyelid tightening. At the time of reporting, across all procedures performed to date, no unexpected or persistent adverse reactions were observed. Limited early imaging demonstrated the expected immediate tissue contraction, and qualitative impressions suggested interval improvements in eyebrow position, upper-eyelid redundancy, and periorbital rhytids at three months; however, these observations are anecdotal and not presented as quantitative outcomes. The author assumes that the novel small applicators may facilitate more controlled vector-based energy delivery, and that the dual-frequency deep mode may theoretically reduce the superficial penetration limitations of conventional small tips. As this manuscript is intended solely to outline a standardized procedural protocol, these assumptions should not be interpreted as evidence-based conclusions. Objective and subjective outcome measures are being collected in an ongoing prospective study. In conclusion, the XERF dual-frequency NMRF system, equipped with its novel small tips, appears to deliver safe, precise, and reproducible nonsurgical periorbital rejuvenation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.